7. Resultados
7.4 Análisis del cumplimiento de los programas de construcción viviendas de interés social y subsidios
7.4.2 Subsidios otorgados para compra
Excluded study Primary reason for exclusion
Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, et al. Patient-reported outcomes in women with breast cancer enrolled in a dual-centre, double-blind, randomised controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 2014;120:381–9
Not EQ-5D
Bonnetain F, Conroy T, Velten M, Jolly D, Mercier M, Causeret S, et al. Impact of response shift in longitudinal postoperative quality of life (QoL) analysis among breast cancer (BC) patients: a randomised multicenter cohort study. J Clin Oncol 2010; Conference (var.pagings):15
Abstract
Brown DS, Trogdon J, Ekwueme DU, Chamiec-Case L, Tangka FK, Guy GP et al. Preference-based estimates of the health utility impacts of breast cancer in women ages 18–44 in the United States. Value Health 2012; Conference(var.pagings):4
Abstract
Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integrative Oncol 2010;8:43–55
Not EQ-5D
Chang J, Couture FA, Young SD, Lau CY, Lee MK. Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Supportive Cancer Therapy 2004;2:52–8
No relevant information on health states
Cheung YB, Lee CF, Luo N, Ng R, Wong NS, Yap YS, et al. Comparison of the measurement properties between the 5-level euroqol group’s 5-dimension (EQ-5D-5l) questionnaire and the functional assessment of cancer therapy-breast (FACT-B) in Asian breast cancer patients. Value Health 2012;15:A605
Abstract
Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema. Cancer 2010;116:3722–31
Inappropriate participants
Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 2001;10:479–86
No relevant information on health states
Coyle D, Grunfeld E, Coyle K, Julian JA, Pond GR, Folkes A, et al. Cost-effectiveness of a survivorship care plan for breast cancer survivors. J Clin Oncol 2011;
Conference(var.pagings):15
Abstract
Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European J Health Econ 2010;11:427–34
Not primary research
Dabakuyo TS, Guillemin F, Conroy T, Velten M, Jolly D, Mercier M, et al. Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study. Qual Life Res 2013;22:1–11
Not EQ-5D
de KM, Dirksen CD, Kessels AG, van der Weijden T, van de Velde CJ, Roukema JA, et al. Cost-effectiveness of a short stay admission programme for breast cancer surgery. Acta Oncol 2010;49:338–46
No relevant information on health states
Dolbeault S, Cayrou S, Bredart A, Viala AL, Desclaux B, Saltel P, et al. The effectiveness of a psycho-educational group after early-stage breast cancer treatment: results of a randomised French study. Psycho-Oncology 2009;18:647–56
Not EQ-5D
Domeyer PJ, Sergentanis TN, Zagouri F, Zografos GC. Health-related quality of life in vacuum-assisted breast biopsy: short-term effects, long-term effects and predictors. Health Qual Life Outcomes 2010;8:11
Inappropriate participants
Fang P, Tan KS, Troxel AB, Rengan R, Freedman G, Lin LL. High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy. Breast Cancer Res Treat 2013;141:125–33
Excluded study Primary reason for exclusion
Fang P, Tan K, Troxel A, Rengan R, Freedman G, Lin L. High BMI associated with worse quality of life in breast cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Physics 2013;87(Suppl. 1):S607
No relevant information on health states
Farkkila N, Roine R, Jahkola T, Sintonen H, Hanninen J, Taari K, et al. Health state utilities in breast cancer. Value Health 2011; Conference (var.pagings):7
Abstract
Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E, Pratt T, et al. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomised trial with economic evaluation. Breast Cancer Res Treat 2010;124:163–75
No relevant information on health states
Hayran M, Cakir B, Cilingiroglu N, Erman M, Kilickap S, Ozisik YY, et al. Validation and clinical evaluation of different quality of life (QoL) scales in patients (pts) with breast cancer (BC) in Turkey. J Clin Oncol 2011; Conference (var.pagings):15
Abstract
Jansen SJ, Otten W, van de Velde CJ, Nortier JW, Stiggelbout AM. The impact of the perception of treatment choice on satisfaction with treatment, experienced
chemotherapy burden and current quality of life. Br J Cancer 2004;91:56–61
No relevant information on health states
Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, et al. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost-effective? Cancer 2006;107:2328–36
Not primary research
Katharina WA, Schumacher A. Social connotations of breast cancer-work in progress. Psycho-Oncology 2013;22:222
Abstract
Kimman ML, Dirksen CD, Falger P, Voogd A, Kessels A, Gijsen B, et al. Results of an RCT investigating the cost-effectiveness of four follow-up strategies after breast cancer. Eur J Cancer, Supplement 2009; Conference (var.pagings):2–3
Abstract
Kimman ML, Dirksen CD, Lambin P, Boersma LJ. Responsiveness of the EQ-5D in primary breast cancer survivors. EJC Suppl 2008;6:73–4
Abstract
Kimman ML, Dirksen CD, Voogd AC, Falger P, Gijsen BC, Thuring M, et al. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: results of an RCT. Eur J Cancer 2011;47:1175–85
Inappropriate participants
Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, et al. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group’s 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res 2013;22:1745–51
Inappropriate participants
Lee CF, Ng R, Luo N, Wong NS, Yap YS, Lo SK, et al. The English and Chinese versions of the five-level EuroQoL Group’s five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients. Supportive Care Cancer 2013;21:201–9
Inappropriate participants
Lee J-A, Kim S-Y, Kim Y, Oh J, Kim H-J, Jo D-Y, et al. Comparison of health-related quality of life between cancer survivors treated in designated cancer centres and the general public in Korea. Japanese J Clin Oncol 2014;44:141–52
No relevant information on health states
Lovrics PJ, Cornacchi SD, Barnabi F, Whelan T, Goldsmith CH. The feasibility and responsiveness of the health utilities index in patients with early-stage breast cancer: a prospective longitudinal study. Qual Life Res 2008;17:333–45
Not EQ-5D
Matalqah LM, Radaideh KM, Yusoff ZM, Awaisu A. Health-related quality of life using EQ-5D among breast cancer survivors in comparison with age-matched peers from the general population in the state of Penang, Malaysia. J Public Health 2011;19:475–80
Inappropriate participants
Milne RJ, Heaton-Brown KH, Hansen P, Thomas D, Harvey V, Cubitt A. Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics 2006;24:281–92
Inappropriate participants
Moro-Valdezate D, Peiro S, Buch-Villa E, Caballero-Garate A, Morales-Monsalve MD, Martinez-Agullo A, et al. Evolution of Health-Related Quality of Life in Breast Cancer Patients during the First Year of Follow-Up. J Breast Cancer 2013;16:104–11
No relevant information on health states
Ng R, Lee CF, Wong NS, Yap YS, Lo SK, Wong C, et al. Measurement properties and equivalence of the English and Chinese versions of the new 5-level EQ-5D in Asian breast cancer patients. Eur J Cancer 2011; Conference(var.pagings):S235
Excluded study Primary reason for exclusion
Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat 2004;87:45–57
Not EQ-5D
Peasgood T, Ward SE, Brazier J. Health state utility values in breast cancer: a review and metaanalysis. Value Health 2010; Conference(var.pagings):7
Not primary research
Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer treatment: impact on health state preferences. Med Care 2002;40:1068–79
Not EQ-5D
Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol 2003;21:1139–46
Not EQ-5D
Postma EL, Koffijberg H, Verkooijen HM, Witkamp AJ, van den Bosch MA, van HR. Cost-effectiveness of radioguided occult lesion localisation (ROLL) versus wire-guided localisation (WGL) in breast conserving surgery for nonpalpable breast cancer: results from a randomised controlled multicenter trial. Ann Surg Oncol 2013;20:2219–26
No relevant information on health states
Rand KL, Otte JL, Flockhart D, Hayes D, Storniolo AM, Stearns V et al. Modelling hot flushes and quality of life in breast cancer survivors. Climacteric 2011;14:171–80
No relevant information on health states
Shimozuma K, Shiroiwa T, Fukuda T, Mori M, Ohashi Y, Watanabe T. Comparison of Eq-5D Score Between Treatment with 4 Cycles of Anthracycline Followed by 4 Cycles of Taxane and 8 Cycles of Taxane for Node Positive Breast Cancer Patients After Surgery: N-Sas Bc 02 Trial. Value Health 2010;13:A274
Abstract
Shiroiwa T, Fukuda T, Shimozuma K, Kuranami M, Suemasu K, Ohashi Y, et al. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial. Value Health 2011;14:746–751
No relevant information on health states
Slovacek L, Slovackova B, Slanska I, Petera J, Priester P, Filip S, et al. Depression
symptoms and health-related quality of life among patients with metastatic breast cancer in programme of palliative cancer care. Neoplasma 2009;56:467–72
No relevant information on health states
Slovacek L, Slovackova B, Slanska I, Petera J, Priester P. Quality of life and depression among metastatic breast cancer patients. Med Oncol 2010;27:958–9
Abstract
Sun Y, Kang E, Heo C, Kim D, Hwang Y, Yom C, et al. Comparison of Quality of Life According to the Surgical Techniques Among Breast Cancer Survivors. Breast 2013;22(Suppl. 1):S117–18
Abstract
Sura K, Tan K, Freedman GM, Troxel AB, Lin LL. Factors affecting breast cancer patient quality of life in association with radiation. Int J Rad Oncol Biol Phys 2013; 87(Suppl. 1):S115–16
Abstract
Takei H, Ohsumi S, Shimozuma K, Ohashi Y, Fujiki Y, Suemasu K, et al. Health-related quality-of-life and psychological distress of breast cancer patients after surgery during phase III randomised trial comparing tamoxifen, exemestane, and anastrozole: N-SAS BC 04. Breast Cancer Res Treat 2006;100(Suppl. 1):S189–90
Not EQ-5D
Teckle P, Peacock S, McTaggart-Cowan H, van der Hoek K, Chia S, Melosky B, et al. The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes 2011;9:106
Inappropriate participants
Velthuis MJ, May AM, Koppejan-Rensenbrink RA, Gijsen BC, van BE, de Wit GA, et al. Physical Activity during Cancer Treatment (PACT) Study: design of a randomised clinical trial. BMC Cancer 2010;10:272
Not EQ-5D
Verkooijen HM, Buskens E, Peeters PH, Borel Rinkes IH, de Koning HJ, van Vroonhoven TJ, et al. Diagnosing non-palpable breast disease: short-term impact on quality of life of large-core needle biopsy versus open breast biopsy. Surg Oncol 2002;10:177–81
Inappropriate participants
von Meyenfeldt MF, de KM, Kessels AGH, van der Weijden T, Bell AVRJ, Roukema JA, et al. Economic evaluation of a short stay admission programme for breast cancer surgery in four hospitals in the Netherlands. Eur J Cancer, Supplement 2010; Conference(var.pagings):3
Abstract
Wilking N, Bernow M, Kossler I, Wilking U, Jonsson B. Health related quality of life (HRQoL) in Swedish relapse free breast cancer patients. A study of EQ5D and TTO in a patient advocacy population. Cancer Res 2009; 69:780S–1S
Excluded study Primary reason for exclusion
Wu Y, Segreti A, Cella D, DiLeo A, Amonkar M, Koehler M, et al. Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB(2+) patients– quality of Life (QOL) results. EJC Suppl 2008;6:171
Abstract
Yaqata H, Iwase T, Ohtsu H, Komoike Y, Saji S, Takei H, et al. Baseline assessment of patient-reported outcomes (PROs) for breast cancer patients after 5-years of endocrine treatment in a randomised clinical trial: NSAS-BC 05. Breast 2011;20(Suppl. 1):S68
Abstract
Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577–89
No relevant information on health states
Zhou X, Segreti A, Cella D, Cameron D, Geyer C, Amonkar M, et al. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC)– quality of Life (QOL) assessment. EJC Supplements 2008;6:216–17